Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Veracyte, Inc.

Cost of Revenue Trends: ADMA Biologics, Inc. vs. Veracyte, Inc.

In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. From 2014 to 2023, ADMA Biologics, Inc. and Veracyte, Inc. have shown significant shifts in their cost of revenue. ADMA Biologics, Inc. experienced a staggering 4,400% increase, from approximately $3.7 million in 2014 to $169 million in 2023. This growth reflects their expanding operations and increased production capabilities. Meanwhile, Veracyte, Inc. saw a 580% rise, reaching $113 million in 2023 from $16.6 million in 2014, indicating a steady scaling of their diagnostic services. Notably, both companies showed a marked increase in 2021, with ADMA's costs rising by 30% and Veracyte's by 80% compared to the previous year. These trends highlight the dynamic nature of the biotech industry, where strategic investments in production and innovation drive financial outcomes.